About the Study
Dose Escalation Study of iopofosine (also known as I-131-CLR1404) in Patients with Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is an incurable, monoclonal proliferation of plasma cells. Approximately 80,000 Americans are affected by MM with approximately 22,000 new cases diagnosed and 11,000 deaths each year. The introduction of newer therapies in the past twenty years, such as autologous stem cell transplantation and novel agents such as proteasome inhibitors and immune modulating drugs has improved outcomes, with current median overall survival estimates of 3-10 years depending on a number of patient-, disease- and treatment-related factors. However, despite these innovations, myeloma relapse is inevitable. Therefore, there is a clear need for improved therapies for MM and, in particular, for relapsed disease.
Iopofosine is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (iopofosine) is radiolabeled with the isotope iodine-131 (I-131). Radioiodinated iopofosine has been evaluated in over 60 xenograft and spontaneous (transgenic) tumor models. In all but two cases of hepatocellular carcinoma, iopofosine demonstrated selective cancer cell uptake and retention. In various rodent tumor models, iopofosine has also demonstrated tumor growth delay and prolongation of survival.